1,847 results on '"Bivalacqua, Trinity J."'
Search Results
2. Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma
3. Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial
4. Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial
5. Prostate-Specific Antigen Screening in Smokers: A Comprehensive Analysis Using a National Behavioral Survey
6. Reply by Authors
7. Clinical Practice Patterns for Surgical Shunts and Penile Prosthesis Placement in Men With Priapism: A Retrospective Large Claims Database Analysis
8. Reply by Authors
9. BLADDER PRESERVATION in localized, muscle-invasive bladder cancer: Current state of affairs
10. Clinicopathologic and Survival After Cystectomy Outcomes in Squamous Cell Carcinoma of the Bladder
11. Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: SWOG S1605
12. Intravenous BCG vaccination reduces SARS-CoV-2 severity and promotes extensive reprogramming of lung immune cells
13. Practice Patterns Regarding Female Reproductive Organ-Sparing and Nerve-Sparing Radical Cystectomy Among Urologic Oncologists in the United States
14. Multicenter evaluation of neoadjuvant and induction gemcitabine–carboplatin versus gemcitabine–cisplatin followed by radical cystectomy for muscle-invasive bladder cancer
15. A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study
16. Systematic review of the impact of a plant-based diet on prostate cancer incidence and outcomes
17. Clinical Management
18. Pathologic and survival outcomes following radical cystectomy for “progressive” and “de novo” muscle-invasive bladder cancer: A meta-analysis stratified by neoadjuvant chemotherapy status
19. Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer – Clinical Activity and Whole Transcriptome Analysis
20. Reply by Authors
21. MP68-01 SMOKING, EXERCISE AND PHYSICAL ACTIVITY ARE INDEPENDENTLY ASSOCIATED WITH MENTAL HEALTH IN PROSTATE CANCER PATIENTS AND SURVIVORS: BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM (BRFSS) STUDY
22. PD58-07 THE ROLE OF EXERCISE ON PHYSICAL AND MENTAL HEALTH IN KIDNEY CANCER
23. MP77-10 RESIDUAL CANCER AT RADICAL CYSTECTOMY WITH OR WITHOUT NEOADJUVANT CHEMOTHERAPY FOR CLINICAL T2 MUSCLE-INVASIVE BLADDER CANCER: A PATHOLOGIC STAGE-MATCHED COMPARISON
24. MP08-15 SMOKING STATUS IS ASSOCIATED WITH POOR MENTAL HEALTH IN BLADDER CANCER PATIENTS AND SURVIVORS
25. MP16-14 A PHASE II TRIAL OF INTRAVESICAL GEMCITABINE AND DOCETAXEL (GEMDOCE) IN THE TREATMENT OF BCG-NAÏVE NON-MUSCLE INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER
26. PD38-12 NATIONAL PERFORMANCE OF LYMPHADENECTOMY FOR MUSCLE-INVASIVE UROTHELIAL CANCER AND AN EXPLORATORY ANALYSIS TO DEFINE OPTIMAL LYMPH NODE YIELD BASED ON SOUTHWEST ONCOLOGY GROUP S1011 TRIAL
27. PD48-01 EFFICACY OF NADOFARAGENE FIRADENOVEC-VNCG FOR PATIENTS WITH BACILLUS CALMETTE-GUÉRIN-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER: FINAL RESULTS FROM A PHASE 3 TRIAL
28. MP55-20 THE EFFECT OF NEONATAL UPPER AND LOWER URINARY TRACT OBSTRUCTION ON THE GASTROINTESTINAL MICROBIOME IN a MURINE ANIMAL MODEL
29. MP49-06 PROSTATE SPECIFIC ANTIGEN SCREENING AMONGST SMOKERS: A U.S. NATIONAL BEHAVIORAL ANALYSIS
30. Intermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group
31. International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin–exposed High-risk Non–muscle-invasive Bladder Cancer
32. Single-cell Transcriptomics Uncover a Novel Role of Myeloid Cells and T-lymphocytes in the Fibrotic Microenvironment in Peyronie’s Disease
33. Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancer
34. Safety and Efficacy of Reproductive Organ-Sparing Radical Cystectomy in Women With Variant Histology and Advanced Stage
35. Multi-Institution Evaluation of Sequential Intravesical Gemcitabine and Docetaxel in the Treatment of Bacillus Calmette-Guerin Naïve Patients with Non-Muscle Invasive Bladder Cancer
36. Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer
37. A Phase II Trial of Intravesical Gemcitabine and Docetaxel in the Treatment of Bacillus Calmette-Guérin‒Naïve Nonmuscle-Invasive Urothelial Carcinoma of the Bladder
38. THE RELATIONSHIP BETWEEN SMOKING STATUS AND POOR MENTAL HEALTH IN BLADDER CANCER PATIENTS AND SURVIVORS
39. EFFICACY OF INTRAVESICAL NADOFARAGENE FIRADENOVEC FOR PATIENTS WITH BCG-UNRESPONSIVE CARCINOMA IN SITU OF THE BLADDER: 36-MONTH FOLLOW-UP FROM A PHASE 3 TRIAL
40. COMPARISON OF APIXABAN VERSUS ENOXAPARIN FOR EXTENDED PROPHYLAXIS AFTER RADICAL CYSTECTOMY (CARE)
41. PROSTATE SPECIFIC ANTIGEN SCREENING AMONGST SMOKERS: A U.S. NATIONAL BEHAVIORAL ANALYSIS
42. ASSESSING THE CLINICAL IMPACT AND COSTS OF INCISIONAL NEGATIVE PRESSURE WOUND THERAPY FOR PREVENTING SURGICAL WOUND COMPLICATIONS AFTER RADICAL CYSTECTOMY
43. UNDERSTANDING THE RELATIONSHIP BETWEEN INSURANCE TYPE AND TESTICULAR GERM CELL TUMORS STAGE PRESENTATION USING THE NATIONAL CANCER DATABASE (NCDB)
44. Predictive models of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer using nuclear morphology and tissue architecture
45. Preclinical evaluation of a hypotonic docetaxel nanosuspension formulation for intravesical treatment of non-muscle-invasive bladder cancer
46. 100 years of Bacillus Calmette–Guérin immunotherapy: from cattle to COVID-19
47. Increased Level of Tumor Necrosis Factor-Alpha (TNF-α) Leads to Downregulation of Nitrergic Neurons Following Bilateral Cavernous Nerve Injury and Modulates Penile Smooth Tone
48. Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer
49. Recombinant BCGs for tuberculosis and bladder cancer
50. Phosphodiesterase Type 5 Inhibitors and Selective Estrogen Receptor Modulators Can Prevent But Not Reverse Myofibroblast Transformation in Peyronie's Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.